Literature DB >> 9292242

Relationship between respiratory failure and plasma noradrenaline levels in amyotrophic lateral sclerosis.

A Yamashita1, Y Koike, A Takahashi, M Hirayama, N Murakami, G Sobue.   

Abstract

We evaluated plasma noradrenaline (NA) levels at test and during head-up tilt test in 20 patients with sporadic amyotrophic lateral sclerosis (ALS). Their fasting plasma NA levels ranged from 195 to 4227 pg/ml. The average plasma NA level was 483 pg/ml in five ambulatory patients, 341 in two wheelchair-bound patients, 1264 in 11 bedridden patients, and 208 in two respirator-dependent patients whose disability grading was the worst among the four groups. Arterial carbon dioxide (PCO2) was evaluated as a measure of respiratory function. The coefficient of correlation between PCO2 and plasma NA was r = 0.654 (p < 0.01). Either respiratory failure or lower motor neuron dysfunction may relate to the elevation of plasma NA levels. In the two bedridden patients, plasma NA levels and heart rate at rest increased significantly as the disease progressed. Cardiovascular responses to head-up tilting were normal. These data suggest that the elevation of plasma NA levels may be related to progression of respiratory failure and lower motor neuron dysfunction. In conclusion, sympathetic hyperactivity in ALS is considered to be not primary, but secondary to somatic motor disabilities and respiratory failure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9292242     DOI: 10.1007/BF02267978

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  15 in total

Review 1.  Diagnostic criteria in clinical trials.

Authors:  M H Brooke
Journal:  Neurology       Date:  1996-10       Impact factor: 9.910

2.  [Plasma vasopressin responses to orthostasis and hypertonic saline infusion in progressive autonomic failure].

Authors:  Y Senda; Y Koike; Y Oiso; Y Matsuoka; A Takahashi
Journal:  Rinsho Shinkeigaku       Date:  1988-11

3.  El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors.

Authors:  B R Brooks
Journal:  J Neurol Sci       Date:  1994-07       Impact factor: 3.181

4.  Microneurographic analysis of muscle sympathetic nerve activity in amyotrophic lateral sclerosis.

Authors:  K Shindo; S Tsunoda; Z Shiozawa
Journal:  Clin Auton Res       Date:  1993-04       Impact factor: 4.435

5.  [Autonomic nervous disorder in motor neuron disease].

Authors:  N Tamura
Journal:  Rinsho Shinkeigaku       Date:  1984-12

6.  Autonomic function in amyotrophic lateral sclerosis: a study of cardiovascular responses.

Authors:  C Sachs; S Conradi; L Kaijser
Journal:  Acta Neurol Scand       Date:  1985-05       Impact factor: 3.209

7.  [Disturbance of micturition in amyotrophic lateral sclerosis].

Authors:  T Hattori; K Hirayama; K Yasuda; J Shimazaki
Journal:  Rinsho Shinkeigaku       Date:  1983-03

8.  [Increased sympathetic nervous activity in motor neuron disease--a hemodynamic study].

Authors:  N Tamura; K Shimazu; K Oh-iwa; H Kim; K Hamaguchi
Journal:  Rinsho Shinkeigaku       Date:  1983-02

9.  Sympathetic iris function in amyotrophic lateral sclerosis.

Authors:  A Bogucki; R Salvesen
Journal:  J Neurol       Date:  1987-04       Impact factor: 4.849

10.  Norepinephrine and gamma-aminobutyric acid in amyotrophic lateral sclerosis.

Authors:  M G Ziegler; B R Brooks; C R Lake; J H Wood; S J Enna
Journal:  Neurology       Date:  1980-01       Impact factor: 9.910

View more
  1 in total

1.  Pilot Study of Real-World Monitoring of the Heart Rate Variability in Amyotrophic Lateral Sclerosis.

Authors:  Alexander A Brown; Bradley J Ferguson; Vovanti Jones; Bruce E Green; Justin D Pearre; Ifeoma A Anunoby; David Q Beversdorf; Richard J Barohn; Carmen M Cirstea
Journal:  Front Artif Intell       Date:  2022-07-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.